What is Cyclerion Therapeutics Inc's earnings per share (EPS)?

Cyclerion Therapeutics Inc (CYCN) reported diluted earnings per share of $-1.11 for fiscal year 2025. This represents a 8.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cyclerion Therapeutics Inc Financials

CYCN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Cyclerion Therapeutics Inc (CYCN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CYCN FY2025 2026-04-30

Tiny revenue, expense cuts, and outside financing are the main forces keeping Cyclerion's cash position stable.

In FY2025, $3.3M of financing inflow almost matched -$3.3M of operating cash flow. That is why cash still ended the year near $3.2M: with revenue only $2.1M, the steady cash balance was created by capital raising, not by internally generated cash.

The business has been downsized to reduce burn: over the last two annual periods, SG&A plus R&D fell by about $2.6M. That makes the smaller losses look more like the result of a leaner cost base than a stronger revenue engine, because sales were still only $2.1M in FY2025.

Liquidity looks comfortable in the short term: a 5.2x current ratio and just $900K of total liabilities leave little near-term balance-sheet pressure. But this clean balance sheet coexists with continuing cash burn, so today's solvency comes from keeping the organization small and equity-funded rather than from durable cash generation.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Cyclerion Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Cyclerion Therapeutics Inc has an operating margin of -239.8%, meaning the company retains $-240 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -181.4% the prior year.

Leverage

100

Cyclerion Therapeutics Inc carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.15, Cyclerion Therapeutics Inc holds $5.15 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Cyclerion Therapeutics Inc generates a -38.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -34.5% the prior year.

Piotroski F-Score Weak

1/9

Cyclerion Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.94x

For every $1 of reported earnings, Cyclerion Therapeutics Inc generates $0.94 in operating cash flow (-$3.3M OCF vs -$3.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.1M

YoY+3.7%

5Y CAGR-2.0%

Cyclerion Therapeutics Inc generated $2.1M in revenue in fiscal year 2025. This represents an increase of 3.7% from the prior year.

EBITDA

N/A

Net Income

-$3.5M

YoY-15.4%

Cyclerion Therapeutics Inc reported -$3.5M in net income in fiscal year 2025. This represents a decrease of 15.4% from the prior year.

EPS (Diluted)

$-1.11

YoY+8.3%

Cyclerion Therapeutics Inc earned $-1.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 8.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.2M

YoY+0.2%

5Y CAGR-43.1%

Cyclerion Therapeutics Inc held $3.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+50.1%

5Y CAGR-35.4%

Cyclerion Therapeutics Inc had 4M shares outstanding in fiscal year 2025. This represents an increase of 50.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-239.8%

YoY-58.4pp

5Y CAGR+3299.6pp

Cyclerion Therapeutics Inc's operating margin was -239.8% in fiscal year 2025, reflecting core business profitability. This is down 58.4 percentage points from the prior year.

Net Margin

-170.1%

YoY-17.3pp

5Y CAGR+3218.5pp

Cyclerion Therapeutics Inc's net profit margin was -170.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 17.3 percentage points from the prior year.

Return on Equity

-38.8%

YoY-4.3pp

5Y CAGR+92.0pp

Cyclerion Therapeutics Inc's ROE was -38.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$959K

YoY+235.3%

5Y CAGR-55.7%

Cyclerion Therapeutics Inc invested $959K in research and development in fiscal year 2025. This represents an increase of 235.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

CYCN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.1M+3.7%	$2.0M	$0-100.0%	$297K-92.5%	$3.9M+71.7%	$2.3M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$959K+235.3%	$286K-81.1%	$1.5M-74.7%	$6.0M-84.1%	$37.6M-33.3%	$56.4M
SG&A Expenses	$6.1M+14.0%	$5.3M-34.3%	$8.1M-36.8%	$12.9M-37.6%	$20.6M-28.4%	$28.8M
Operating Income	-$5.0M-37.1%	-$3.6M+72.0%	-$13.0M+30.1%	-$18.5M+66.4%	-$55.2M+32.1%	-$81.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$3.5M-15.4%	-$3.1M+41.9%	-$5.3M+88.1%	-$44.1M+14.7%	-$51.6M+33.6%	-$77.8M
EPS (Diluted)	$-1.11+8.3%	$-1.21+46.2%	$-2.25+88.9%	$-20.28-1436.4%	$-1.32	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0-100.0%	$1.0M+17.1%	$875K+840.9%	$93K+14.8%	$81K	N/A	$194K	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$730K+40.7%	$519K+49.1%	$348K+521.4%	$56K+55.6%	$36K	N/A	$81K-22.9%	$105K
SG&A Expenses	$2.5M+84.4%	$1.3M-12.3%	$1.5M-10.3%	$1.7M+13.8%	$1.5M	N/A	$1.2M-3.0%	$1.3M
Operating Income	-$3.2M-282.9%	-$838K+16.7%	-$1.0M+39.8%	-$1.7M-14.8%	-$1.5M	N/A	-$1.1M+18.5%	-$1.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.2M-297.6%	-$799K+18.1%	-$976K-201.2%	-$324K+77.3%	-$1.4M	N/A	-$723K+45.3%	-$1.3M
EPS (Diluted)	$-0.76	N/A	$-0.30-172.7%	$-0.11+80.4%	$-0.56	N/A	$-0.29+45.3%	$-0.53

CYCN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.0M+4.3%	$9.6M-28.4%	$13.4M-26.0%	$18.1M-69.5%	$59.3M-48.6%	$115.4M
Current Assets	$4.6M+9.7%	$4.2M-47.3%	$8.0M-45.9%	$14.8M-73.3%	$55.5M-5.2%	$58.5M
Cash & Equivalents	$3.2M+0.2%	$3.2M-57.3%	$7.6M-43.4%	$13.4M-75.2%	$54.0M-0.8%	$54.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.0M+79.9%	$556K	$0-100.0%	$96K-4.0%	$100K	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$900K+24.1%	$725K-65.2%	$2.1M-72.6%	$7.6M-31.2%	$11.1M-80.2%	$55.9M
Current Liabilities	$900K+24.1%	$725K-65.2%	$2.1M-72.6%	$7.6M-31.2%	$11.1M-34.6%	$17.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.1M+2.7%	$8.8M-21.6%	$11.3M+8.0%	$10.5M-78.3%	$48.2M-18.9%	$59.5M
Retained Earnings	-$271.0M-1.3%	-$267.5M-1.2%	-$264.4M-2.0%	-$259.2M-20.5%	-$215.1M-31.6%	-$163.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$8.5M-14.8%	$10.0M-4.1%	$10.4M+11.2%	$9.4M-4.8%	$9.8M+2.8%	$9.6M+7.6%	$8.9M-11.6%	$10.1M
Current Assets	$3.1M-33.4%	$4.6M-8.5%	$5.1M+26.0%	$4.0M-10.6%	$4.5M+6.4%	$4.2M+19.1%	$3.5M-24.8%	$4.7M
Cash & Equivalents	$2.8M-12.9%	$3.2M-29.1%	$4.6M+52.0%	$3.0M-17.4%	$3.6M+12.6%	$3.2M+12.5%	$2.9M-37.4%	$4.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$1.0M+900.0%	$100K-81.0%	$525K-9.6%	$581K+4.5%	$556K+1163.6%	$44K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.7M+90.4%	$900K+2.6%	$877K+9.6%	$800K-25.0%	$1.1M+47.2%	$725K+3.6%	$700K-45.4%	$1.3M
Current Liabilities	$1.7M+90.4%	$900K+2.6%	$877K+9.6%	$800K-25.0%	$1.1M+47.2%	$725K+3.6%	$700K-45.4%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.8M-25.3%	$9.1M-4.7%	$9.5M+11.3%	$8.6M-2.4%	$8.8M-0.8%	$8.8M+8.0%	$8.2M-6.7%	$8.8M
Retained Earnings	-$274.2M-1.2%	-$271.0M-0.3%	-$270.2M-0.4%	-$269.2M-0.1%	-$268.9M-0.5%	-$267.5M+0.2%	-$268.0M-0.3%	-$267.3M

CYCN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.3M+23.5%	-$4.3M+79.6%	-$21.2M+47.7%	-$40.6M-11.2%	-$36.5M+49.6%	-$72.5M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$7K-99.5%	$1.5M
Free Cash Flow	N/A	N/A	N/A	-$40.6M-11.2%	-$36.5M+50.7%	-$74.0M
Investing Cash Flow	N/A	$0-100.0%	$10.4M	$0-100.0%	$1.5M+7994.4%	$18K
Financing Cash Flow	$3.3M	$0-100.0%	$5.0M+17224.1%	$29K-99.9%	$30.8M+9.6%	$28.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.2M+25.5%	-$1.6M-498.1%	-$264K+47.5%	-$503K+48.0%	-$968K-368.9%	$360K+121.0%	-$1.7M-55.2%	-$1.1M
Capital Expenditures	$66K	N/A	N/A	N/A	$0	N/A	N/A	N/A
Free Cash Flow	-$1.2M	N/A	N/A	N/A	-$968K	N/A	N/A	N/A
Investing Cash Flow	-$66K	N/A	N/A	N/A	$0	$0	$0	N/A
Financing Cash Flow	$825K+228.7%	$251K-86.3%	$1.8M+1504.6%	-$130K-109.5%	$1.4M	$0	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CYCN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-239.8%-58.4pp	-181.4%	N/A	-6242.4%-4842.2pp	-1400.2%+2139.2pp	-3539.4%
Net Margin	-170.1%-17.3pp	-152.8%	N/A	-14841.1%-13530.9pp	-1310.2%+2078.4pp	-3388.6%
Return on Equity	-38.8%-4.3pp	-34.5%+12.1pp	-46.6%+375.1pp	-421.7%-314.7pp	-107.0%+23.7pp	-130.8%
Return on Assets	-35.3%-3.4pp	-31.9%+7.4pp	-39.4%+204.5pp	-243.8%-156.8pp	-87.1%-19.6pp	-67.4%
Current Ratio	5.15-0.7	5.83+2.0	3.85+1.9	1.94-3.1	5.00+1.6	3.45
Debt-to-Equity	0.10+0.0	0.08-0.1	0.18-0.5	0.73+0.5	0.23-0.7	0.94
FCF Margin	N/A	N/A	N/A	-13673.7%-12747.2pp	-926.5%+2297.1pp	-3223.6%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-3961.7%-3880.0pp	-81.8%+33.2pp	-115.0%+1682.9pp	-1797.9%+0.9pp	-1798.8%	N/A	-581.4%	N/A
Net Margin	-1764.2%-1686.3pp	-78.0%+33.6pp	-111.5%+236.8pp	-348.4%+1415.8pp	-1764.2%	N/A	-372.7%	N/A
Return on Equity	-46.8%-38.0pp	-8.8%+1.4pp	-10.2%-6.5pp	-3.8%+12.5pp	-16.3%	N/A	-8.8%+6.2pp	-15.0%
Return on Assets	-37.4%-29.3pp	-8.0%+1.4pp	-9.4%-5.9pp	-3.5%+11.1pp	-14.5%	N/A	-8.1%+5.0pp	-13.1%
Current Ratio	1.80-3.3	5.15-0.6	5.78+0.8	5.03+0.8	4.21-1.6	5.83+0.8	5.07+1.4	3.68
Debt-to-Equity	0.25+0.2	0.100.0	0.090.0	0.09-0.0	0.12+0.0	0.080.0	0.09-0.1	0.15
FCF Margin	-1533.3%	N/A	N/A	N/A	-1195.1%	N/A	N/A	N/A

Similar Companies

Galmed Pharmaceu GLMD

$4.3M

Vyne Therapeutics Inc VYNE

$22.4M

Impact Biomedical, Inc. IBO

$59.3M

Dogwood Therapeutics DWTX

$66.1M

Aeon Biopharma AEON

$21.1M

Frequently Asked Questions

What is Cyclerion Therapeutics Inc's annual revenue?

Cyclerion Therapeutics Inc (CYCN) reported $2.1M in total revenue for fiscal year 2025. This represents a 3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cyclerion Therapeutics Inc's revenue growing?

Cyclerion Therapeutics Inc (CYCN) revenue grew by 3.7% year-over-year, from $2.0M to $2.1M in fiscal year 2025.

Is Cyclerion Therapeutics Inc profitable?

No, Cyclerion Therapeutics Inc (CYCN) reported a net income of -$3.5M in fiscal year 2025, with a net profit margin of -170.1%.

What is Cyclerion Therapeutics Inc's operating margin?

Cyclerion Therapeutics Inc (CYCN) had an operating margin of -239.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cyclerion Therapeutics Inc's net profit margin?

Cyclerion Therapeutics Inc (CYCN) had a net profit margin of -170.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cyclerion Therapeutics Inc's return on equity (ROE)?

Cyclerion Therapeutics Inc (CYCN) has a return on equity of -38.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cyclerion Therapeutics Inc's operating cash flow?

Cyclerion Therapeutics Inc (CYCN) generated -$3.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cyclerion Therapeutics Inc's total assets?

Cyclerion Therapeutics Inc (CYCN) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Cyclerion Therapeutics Inc spend on research and development?

Cyclerion Therapeutics Inc (CYCN) invested $959K in research and development during fiscal year 2025.

How many shares does Cyclerion Therapeutics Inc have outstanding?

Cyclerion Therapeutics Inc (CYCN) had 4M shares outstanding as of fiscal year 2025.

What is Cyclerion Therapeutics Inc's current ratio?

Cyclerion Therapeutics Inc (CYCN) had a current ratio of 5.15 as of fiscal year 2025, which is generally considered healthy.

What is Cyclerion Therapeutics Inc's debt-to-equity ratio?

Cyclerion Therapeutics Inc (CYCN) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cyclerion Therapeutics Inc's return on assets (ROA)?

Cyclerion Therapeutics Inc (CYCN) had a return on assets of -35.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cyclerion Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Cyclerion Therapeutics Inc (CYCN) had $3.2M in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cyclerion Therapeutics Inc's Piotroski F-Score?

Cyclerion Therapeutics Inc (CYCN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cyclerion Therapeutics Inc's earnings high quality?

Cyclerion Therapeutics Inc (CYCN) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Cyclerion Therapeutics Inc?

Cyclerion Therapeutics Inc (CYCN) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.